Drug intelligence / Profile preview

A-329

Development stage: Unknown
Lead developer: ITabMed
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**A-329** is an investigational bispecific drug developed by ITabMed Co., Ltd., characterized as a CD19 inhibitor and CD3 stimulant, likely functioning as a T-cell engager to redirect T cells against CD19-positive B cells. It is in early-stage development with the highest global R&D status reported as IND Application, indicating preparations for clinical trials, though no specific indications or trial details are confirmed in available data.[7]

Targets

CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on A-329.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-329.

Explore the full profile